Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration. The company's application for marketing licensing of injectable Ruikang trastuzumab was accepted and included in the priority review process.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration. The company's application for marketing licensing of injectable Ruikang trastuzumab was accepted and included in the priority review process.